<div class="article">
	<h3>Technology Brief -- Biocontrol Technology Inc.:
   Company Successfully Tests
   A Vascular Access Device</h3>
	<div class="article-info">
		<ul>
			<li>Author: null</li>
			<li>Date: 07/03/90</li>
		</ul>
	</div>
	<p class="article-leader">Biocontrol Technology Inc. said it concluded a successful
clinical trial on animals of its vascular access device.
   The Indiana, Pa.-based company, a maker and developer of
biomedical devices, said it plans to apply to the Food and
Drug Administration immediately for approval to begin
clinical studies in humans.</p>
	<div class="article-body"><p>Biocontrol's vascular access device, known as the
Bio-Port, is a drug delivery receptacle that is implanted
beneath the skin. The device eliminates skin and blood vessel
damage when repeated injections are necessary, such as in
chemotherapy treatment.</p>
<p>The company said its market research indicates a $50
million annual market for these devices world-wide.</p>
<p></p></div>
</div>
